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Abstract
Background
Community-based randomized controlled trials are often complex pieces of research with
significant challenges around the approach to the community, information provision, and
decision-making, all of which are fundamental to the informed consent process. We con-
ducted a rapid ethical assessment to guide the preparation for and conduct of a randomized
controlled trial of podoconiosis treatment in northern Ethiopia.
Methods
A qualitative study was carried out in Aneded woreda, East Gojjam Zone, Amhara Regional
State from August to September, 2013. A total of 14 In-depth Interviews (IDIs) with
researchers, experts, and leaders, and 8 Focus Group Discussions (FGDs) involving 80
participants (people of both gender, with and without podoconiosis), were conducted. Inter-
views were carried out in Amharic. Data analysis was started alongside collection. Final
data analysis used a thematic approach based on themes identified a priori and those that
emerged during the analysis.
Results
Respondents made a range of specific suggestions, including that sensitisation meetings
were called byworeda or kebele leaders or the police; that Health Extension Workers were
asked to accompany the research team to patients’ houses; that detailed trial information
was explained by someone with deep local knowledge; that analogies from agriculture and
local social organisations be used to explain randomisation; that participants in the ‘delayed’
intervention arm be given small incentives to continue in the trial; and that key community
members be asked to quell rumours arising in the course of the trial.
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Conclusion
Many of these recommendations were incorporated into the preparatory phases of the trial,
or were used during the course of the trial itself. This demonstrates the utility of rapid ethical
assessment preceding a complex piece of research in a relatively research-naive setting.
Author Summary
Community-based randomised controlled trials in developing countries, especially in set-
tings with no research experience, are faced with significant challenges around approaching
the community and obtaining informed consent. We conducted a Rapid Ethical Assess-
ment, a simple and quick qualitative technique involving interviews and focus group dis-
cussions with researchers, experts, community leaders, and community members of both
gender, with and without podoconiosis, the condition being studied. We aimed to explore
optimal methods to provide information about the trial and approaches to the consent pro-
cess preferred by the community. Overall, suggestions were grouped into five domains:
approaching patients, information provision and comprehension, decision making, con-
straints to participation and ways of explaining randomisation and the control group.
These recommendations were used to design the information sheet and consent form and
to make other changes before and during the trial. This study highlights the utility of rapid
ethical assessment prior to clinical trials involving complex procedures and concepts.
Introduction
The Informed Consent (IC) process is a mandatory requirement in clinical research, and its
relevance and specifications are clearly outlined in international, legal and ethical guidelines
such as the Nuremberg Code[1], The Declaration of Helsinki[2], The Belmont Report[3] and
The Council for International Organizations of Medical Sciences (CIOMS)[4]. IC describes a
process in which an individual voluntarily agrees to participate in a research study after the
purpose, risks and alternatives have thoroughly been described. The ethical principle of Respect
for Persons identifies the consent process as containing three key elements: the provision of
information, comprehension of information, and voluntary participation[3]. Researchers are
required to provide potential participants with sufficient information about a trial. This should
include the study objectives, design and procedures to be followed, identification of procedures
which are experimental, risks and benefits of participation, expected duration of the study,
their rights as participants, a disclosure of alternative courses of treatment, extent of confidenti-
ality of records, and an explanation of whom to contact for questions about the research and
research subjects’ rights. Potential participants must be allowed adequate time to make a volun-
tary and informed decision about participation. Provision of information in a language pro-
spective participants are capable of understanding is critical in obtaining genuine informed
consent before they are enrolled in a trial[4–5].
Comprehension of information provided about the research influences the decision to par-
ticipate in a scientific investigation. Many factors shape approaches to implementing informed
consent, including the nature and cultural context of the study[6]. Studies have shown that
information provided in information sheets and informed consent documents may be
completely alien to potential participants. For example, differences between research and free
treatment or aid and randomisation may be difficult for participants to understand[7]. In low-
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income countries, low literacy levels, limited access to health care, lack of familiarity with clini-
cal research and decision-making and consent procedures, may all affect understanding [6, 8].
Thus, when clinical trials are to be conducted in low-income countries, especially in communi-
ties with little or no previous experience of participating in research, providing information
that is both comprehensive and comprehensible may be very challenging.
Additionally, although consent is normally documented in a written, signed and dated con-
sent form, written documentation of informed consent for studies can be particularly problem-
atic in certain cultures[9]. In some areas of the world, both individuals and communities may
be reluctant to put their signatures or thumbprints on a document because of previous experi-
ences of having signed “legal” forms that resulted in political, economic and social victimisa-
tion including loss of property and sanctions against them [10].
Both these issues demonstrate the need to orient requirements specified in international
guidelines to the local context in which a study is to be conducted. Relevant training for field-
workers, discussion with stakeholders, communicating with participants at different stages and
providing incentives are important for successful recruitment and retention of subjects in clini-
cal trials[11]. A genetic study conducted in southern Ethiopia recommended that researchers
should carefully assess tradition of decision making in communities. For example, in the con-
text of southern Ethiopia, families should be approached before individual participants[12].
Rapid ethical assessment (REA) is a brief qualitative intervention designed to map the ethical
terrain of a research setting prior to recruitment of participants and has been proposed as one
means of improving the consent process in research-naïve settings [13–14]. It uses rapid ethno-
graphic techniques to better understand the ethical issues that are relevant to a specific piece of
research in a given study setting. The approach has been used prior to research projects in Ethio-
pia, Cameroon and The Gambia, and has been shown to be feasible in the Ethiopian context [15].
Podoconiosis is a form of lymphoedema (leg swelling) arising in people going barefoot in
highland tropical areas[16]. A recent nationwide mapping indicated clusters of high prevalence
(> 5%) were exclusively found in Amhara, Oromia, and Southern Nations Nationalities and
People’s Regional State, which represent most of the central highlands of Ethiopia[17]. Despite
the high impact of podoconiosis on rural farming communities, treatment has been hampered
by misdiagnosis (chiefly confusion with filarial lymphoedema) and fatalism[18]. We conducted
a REA to guide the preparation for and conduct of a randomized controlled trial of podoconio-
sis treatment in northern Ethiopia. The trial is being conducted in East Gojjam Zone, Amhara
regional state in northern Ethiopia. The primary object of the trial is to test the hypothesis that
community-based treatment of podoconiosis lymphoedema reduces the frequency of acute
dermatolymphangioadenitis episodes (ADLA, ‘acute attacks’) and improves other clinical,
social and economic outcomes. In this study we aimed to explore optimal methods of convey-
ing information about the trial and the approaches to obtaining informed consent preferred by
the community in which the trial was to be carried out [19].
Methods
Study Site
The study was carried out in Amber woreda (district), part of East Gojjam Zone in Amhara
regional state, where the prevalence of podoconiosis in the adult population is 3.4% [20]. The
woreda is located 280 km North West of Addis Ababa and 20 km south east of Debre Markos,
the zonal capital. According to the 2007 Census, Aneded woreda is made up of 19 kebeles
(smallest administrative unit) and has a total population of 91,224, with 89,446 living in rural
kebeles [21]. It has 4 Health Centres and 20 Health Post (HPs). Each HP is staffed with two
trained Health Extension Workers (HEWs), female civil servants implementing the health
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extension package at kebele level under the direct supervision of Health Centers and theWor-
edaHealth Office[22].
According to the Ethiopian Demographic & Health Survey 2011, 62% of women and 37% of
men in Amhara Region cannot read at all[23].
Study design
In-Depth Interviews (IDIs) and Focus Group Discussions (FGDs) were the main methods of
data collection. Items in the semi-structured interview and focus group guides used were
adapted from rapid ethical assessment instruments previously used in Ethiopia and the Gambia
[9, 13]. Slightly differing interview schedules were used for each category of respondent. Items
in the guides were presented in the same order as anticipated in the trial, i.e. approaching
patients, provision of information, decision making, constraints and randomisation. In addi-
tion, the interview guide for researchers and experts included items about how comprehension
of information given about the study should be assessed and application of international ethical
guidelines in the local context. The study was approved by the Research Governance and Ethics
Committee of Brighton & Sussex Medical School and the Institutional Review Board of the
College of Health Sciences, Addis Ababa University. Introductory letters were presented to
regional, zonal and woreda level health authorities.
Participants
These included researchers from Debre Markos University who had conducted studies in the
area, podoconiosis prevention and treatment service providers from International Orthodox
Christian Charities (IOCC), woreda level health and agricultural experts, development agents
and health professionals, kebele, community, iddir (a form of social insurance group) and reli-
gious leaders. Community participants were identified by Health Extension Workers (HEWs)
and a group of ten participants took part in each FGD from three kebeles based on their dis-
tances from the woreda capital: remote and less remote. Accordingly,Wonga Nifasam, Yewobi
andMislawash kebeles were included. A total of 14 IDIs and 8 FGDs were planned. Separate
FGDs for people with podoconiosis and non podoconiosis-affected community members of
both sexes were conducted.
Data collection
The REA was conducted from July to August 2013. Data were collected by a public health
expert and a social anthropologist (both Ethiopians). Individual participants were informed
about the objectives of the study and oral consent obtained. Once permission to participate was
secured, interviews were recorded using digital recorders. The interviews were conducted in
offices and community settings. After the first few interviews, data collection activities were
halted until previously collected data were analyzed. This was to identify themes that emerged
and modify interview guides accordingly. Interviews and FGDs were conducted in the local
language (Amharic), and on average lasted one to one-and-a-half hours, respectively. Core
questions for IDIs and FGDs are given in Table 1.
Data analysis
Data analysis was started alongside collection. First, data were transcribed and translated into
English. This was followed by categorizing and organizing data thematically in accordance
with the objectives of the study. Final data analysis was made using a thematic approach based
on themes identified a priori and those that emerged during the analysis.
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Results
A total of 94 participants (42 females and 52 males) took part in 14 in-depth interviews and 8
Focus Group Discussions (FGDs—10 participants each). The age of participants ranged
between 19 and 80 years. The majority, 79, were married, while 5 were not married and 10
were widowed. The qualifications of the health professionals and experts ranged from
diploma to Master’s degree level. Almost all community participants had little or no formal
education (Table 2). In the following paragraphs, study findings are organized under the
Table 2. Characteristics of the study participants.
Characteristics Number
Sex
Male 52
Female 42
Average age (in years) 38.5
Marital Status
Married 79
Single 5
Widowed 10
Educational Status
Can read and write 10
Cannot read and write 70
Elementary and High School 5
Higher education 9
Podoconiosis status
Affected 40
Non-affected 54
doi:10.1371/journal.pntd.0004531.t002
Table 1. Core questions for in-depth interviews and focus group discussions.
Theme Sample question
Approaching patients From your experience, who in the community do you think can serve as the most practical way of gaining
access to and approaching prospective participants for the trial?
Provision and comprehension of
information
In your opinion, what fundamental information about the trial would you say should be provided to prospective
participants?
From your experience, how does the community prefer to receive information about trial?
Additional items for researchers and experts:
How do requirements in international ethical guidelines compare with local circumstances in Ethiopia?
In your opinion what do you think are the challenges for the practical implementation of requirements in
international ethical guidelines in the Ethiopian context?
How do you suggest patients’ understanding of information given about the study be assessed?
Decision making From your experience how would you explain the norm of decision-making about important situations such as
participating in a study in this community?
What roles do heads of families, family members, relatives and women have in making decisions?
How much time would you say prospective participants need to reach a decision?
Constraints to participation In your opinion, what factors inﬂuence patients’ decision to participate in the study?
Explaining randomisation and delayed
intervention
From your experience what local narratives exist to explain the concept of randomisation?
Can you think of techniques to promote understanding of why some will receive treatment immediately and
some at a later date?
How can the beneﬁt of participating in the trial be explained? (E.g. for delayed treatment group?)
doi:10.1371/journal.pntd.0004531.t001
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following thematic areas: approaching patients, provision and comprehension of informa-
tion, decision making, constraints to participation and explaining randomisation and delayed
intervention.
Approaching patients
The way researchers approach communities and individual participants to provide information
about a study plays a vital role in obtaining informed consent. The approaches described here
could be seen as being at two levels: first approaching the community as a whole followed by
individual participants. Some suggested kebele leaders and law enforcement as key to
approaching the community and individual participants
“The kebele leader will guide you. . .he knows all the patients. The local police department
know where all the patients live, and the two can work together. . .they’ll call patients to a
meeting and everyone will attend, since they respect and obey the orders of the kebele
leader” (P5, Non-patient, Male).
“Without the kebele’s assistance, it will be like walking in darkness. . .you can’t go without
the kebele helping you!” (P6, Non-patient, Male).
Regarding the order of approach, community members suggested that kebele officials
should be approached first. These would then arrange a meeting with the community either
in a kebele compound or in a church on a specific religious day, and information about the
study could be provided.
“For example, you can use St. Michael’s day when everyone will be attending the Church
(P7, Patient, Male).
Once the community is informed about the intended study, researchers can proceed to
approach individual patients for consent. Participants indicated that individuals should be
approached for consent at their homes in one of two ways. The first would be to identify and
train locally known individuals and send them to patients’ houses. Secondly, researchers could
go to patients’ houses accompanied by a local guide.
“We take them [people coming from other places] to peoples’ houses in the community,
greet them and explain the purpose of our visit, they’ll listen and give their responses, we
then continue to next household” (P7, Non-patient, Female).
A range of views was expressed on researchers going house-to-house unaccompanied.
Focus group participants explained that patients would not refuse to meet anyone offering help
to treat their illness:
“It is for their own benefit, so they don’t need a lot of explanation, they’ll accept an invita-
tion to participate” (P3, Non-patient, Female).
However, most preferred the assistance of the Health Extension Workers (HEWs) in reach-
ing individual patients.
“The responsibility should only be given to HEWs, as they go house-to-house to deliver the
various health service packages. Thus, Health Extension Workers know where there’re preg-
nant women, if children were absent from school and also houses of podoconiosis patients”
(Podoconiosis expert 1).
REA Prior to a Clinical Trial
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004531 March 11, 2016 6 / 17
Provision and comprehension of information
In this section, the responses included are mainly those of researchers and podoconiosis experts
because focus group participants rarely discussed the kind of information that should be provided.
International ethical guidelines require that information about potential risks, inconve-
nience or restrictions should be balanced against any possible benefits. It is very interesting and
rather worrying to note, however, that the expert participants in this REA repeatedly suggested
de-emphasizing information on risks or possible negative consequences that participation in
the study may have on individuals.
“We stress the purpose of the study and its importance in improving patients’ condi-
tions. . .patients should not feel too much about risks” (Podoconiosis expert 1).
“When informed about risks, although some may rarely occur, people focus more on
risks instead of the benefits. . .your study has minimal risks associated with participation,
except maybe the discomfort of being identified as a podo patient” (Podoconiosis expert 3).
This invited a follow up question about applicability of other aspects of international ethical
guidelines locally. Participants believed one size would not fit all and that international guide-
lines needed to be contextualized.
“The main problem is adopting guidelines prepared by western standards if we provide lev-
els of information suitable for literate people to those who’re illiterate; it will become boring
and unclear for most community members” (Podoconiosis expert 3).
Similarly, although international ethical guidelines require provision of relevant information
such as contact details of researchers and their institutional affiliation, to assist participants with
information needs and to answer queries, reflecting on previous experience, a researcher said:
“I don’t think the majority in our community will phone requesting additional informa-
tion. . .we have never given contact information to individual participants [laughing]. . .that
information exists only on paper [study document/proposal]. . .if and when they ask, mostly
we show them the introductory letter from the woreda” (Researcher 2).
Different views were offered regarding whether information should be provided in groups
or individually -
“It is preferable to provide information as a group, for example, for people gathered in a
kebele compound. . .once information about the study is presented, inviting a discussion will
help to get people’s opinions. The majority are illiterate so using flyers would be difficult”
(Expert 1).
“We approached individuals on a house-to-house visit. . .explained the purpose of the
study, asked willingness to take part, and where agreed, asked for signature, as indication of
agreement. Then Health ExtensionWorkers collected the data” (Researcher 1).
When it comes to who should provide information, some thought that anyone could pro-
vide information, while others thought the person providing information should thoroughly
understand the cultural milieu of the area -
“Someone who is from that community understands the culture and is trusted by the peo-
ple” (Researcher 2).
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In relation to checking comprehension of information, the simplest way would be asking
potential participants to recount the most important aspects of information provided -
“To check the extent of understanding, ask a few questions focusing on important elements
of the study, repeating questions if necessary” (Researcher 1).
A few FGD participants maintained there was no need for information, and that requesting
willingness to participate suffices, because in the end it is for their own benefit:
“First of all no one will refuse to participate, since they’re all ill” (P3, Patient, Female).
“We all want to be healthy and thus no one will refuse” (P4, Patient, Female).
Finally, when it comes to signing the written consent form, participants stressed the
importance of understanding the study. Experts who had experience conducting research in
the area said:
“I’ve seen people agreeing orally, but refusing to sign the consent form. This is because they
fear the purpose is to confiscate their lands. . .you’ve to clearly explain the purpose and
meaning of signing the form. . .if they trust you, they’ll sign” (Podoconiosis expert 1).
“People in our communities are very fearful of signing anything. If asked to sign some-
thing, they always think it is linked with some form of legal issues, something that will later
result in a legal obligation and responsibility. But, can be achieved through discussion, espe-
cially if community leaders are involved in discussions and made to understand the purpose
clearly” (Podoconiosis expert 2).
Decision making
Participants suggested that consent to participate depends on the type of research. For example,
for short projects and those involving interviews and surveys, obtaining consent may not be
that difficult. However, for long term studies such as the trial in question, which demand con-
siderable investment of time from participants, the decision may require permission of other
family members, especially if the potential participant happens to be the family breadwinner.
Others thought there was no general formula for reaching decisions -
“It varies according to the situation. . .parents decide on behalf of children. Heads of house-
holds both men and women, decide for themselves” (Podoconiosis expert 3).
Several others said that the decision to participate rested with individual patients:
“It is the patients themselves who make that decision” (Community leader).
“They shoulder the disease burden and its social consequences. . .patients decide for
themselves” (Researcher 2).
Others thought that the authority to make a decision differed for men and women. Men
could decide for themselves while women needed to consult and get their spouse’s approval
before consenting
“What we commonly see is, women don’t decide without first consulting with and obtaining
their husband’s permission” (Podoconiosis expert 2).
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However, female participants asserted that both men and women decide after discussing
with family members. Where women are household heads, (through divorce or widowhood),
they decide without consulting others -
“We decide after discussing with family members and considering their advice. . .but some-
times we can decide ourselves” (P2, Non-patient, Female).
“Since we ask men for advice, they do the same before they decide” (P6, Non-patient,
Female).
“I discuss with my neighbours, I don’t decide alone” (P3, Patient, Female).
“I decide on my own, I don’t have anyone to discuss with” (P5, Patient, Female).
Some suggested that in the context of rural Ethiopia, any important decision had to involve
significant other people; family members, relatives, neighbours, community elders and reli-
gious leaders -
“It is hard to get consent without any influence from others. . .in this area [Amhara region];
community leaders have a big influence” (Podoconiosis expert 3).
“In rural areas, individuals don’t live distinct from others. . .individuals’ decisions will be
affected by others and vice versa. Therefore, for long term studies, it’s appropriate to obtain
the family’s permission too” (Researcher 1).
Constraints to participation
Although focus group participants all agreed there were no clear reasons hindering patients
from participating in the trial, in-depth interviewees argued reasons that might deter individu-
als and explained ways to deal with them -
“I think people will be willing to participate, but my concern is our community has expecta-
tions, such as monetary rewards and sometimes for time they spent, when asked, especially
by people from other areas to participate in some activity” (Health Professional).
Participants also said false rumours about the study’s purpose may create misconceptions
which will impact on decisions to participate. Fertile ground for rumours may be created by
botched community sensitisation, and misleading information reaching communities before
the study team had a chance to discuss directly with individuals. In order to prevent miscon-
ceptions, garnering the support of community, religious and political leaders, ensuring clear
understanding of the nature of the study at all levels and proceeding to enter the community in
as short a time interval as possible after district level sensitisation are all important -
“Rural communities are small, close-knit villages, and word about any outside visitors will
spread very quickly. . .personal beliefs such as ‘visitors are talking to people with swollen
legs and their families, it looks like they’re going to give them aid’ will start to fly around”
(Podoconiosis expert 1).
“First, authorities at different levels need to clearly understand the purpose of the study,
risks and benefits followed immediately by entry into the community to break any rumours
that may arise in the intervening period” (Podoconiosis Expert 3).
“People with no connection with the study may be the ones that start false informa-
tion. . .if non-affected people know the purpose of the study; they can stop rumours when
they arise (WoredaHealth Office expert).
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Explaining randomisation and delayed intervention
The main object of this REA was to furnish information on how best to design the consent pro-
cess for a randomised controlled trial of podoconiosis treatment, so conveying the concept of
randomisation was expected to be very important. In the following paragraphs, understanding
of randomisation and local analogies used to help explain randomisation is presented. This is
followed by suggestions on how to keep participants in the delayed treatment group motivated
to continue participating in the trial even when not receiving treatment.
Several local analogies exist that could be used to explain randomisation. The following
social organisations were mentioned -
“Everything from ‘Iqqub’, ‘Mahiber’ and ‘Senbete’ work based on the concept of chance. . .it is
important to show people that everyone has been registered before the lottery is drawn; sim-
ply tell people, we’ll draw similar to iqqub and those who win will be treated immediately and
the rest will wait for a year. . .they’ll understand” (Podoconiosis expert 1, and Health
Professional).
[‘Iqqub’ is an Amharic term used to describe a traditional saving system where people form
groups and pay an agreed amount of money at an agreed interval into a common pool. Each
member of the group, selected randomly, will receive one large sum of money, and this contin-
ues until everyone has received the sum they’ve contributed in the end. ‘Mahiber’ and ‘Senbete’
are terms referring to a voluntary and mutual religious gathering of a group of people in a
church or at home to celebrate a common religious (saint’s) holiday while feeding the poor, on
a rotational basis.]
A health professional with considerable experience working in the woreda provided two
examples of explaining randomisation through agricultural analogies used previously by agri-
cultural experts assessing poultry farming and the use of modern fertilisers in the community:
“Most people were suspicious of modern fertilizers, but after a comparison of the use of
compost with modern fertilizer was made, farmers witnessed the difference in the year’s
crop both yielded and began to use modern fertilizers. A similar example could be the
chicken farms. . .there was a problem of which breed to use; foreign or hybrid chickens,
then experts demonstrated the difference in the number of eggs laid and convinced farmers”
(WoredaHealth Office expert 1).
Several other analogies for randomisation were given in patient and non-patient focus
groups. “Kircha” is an Amharic term to describe the traditional system for sharing the meat of
slaughtered animals (usually a cow or an ox) and “Worefa” a description of waiting in line or of
a waiting list:
“Yes, we know and use lottery method for ‘kircha’. . .but, we haven’t seen this in meetings”
(P All, Non-patient, Female).
“Lottery is lottery and ‘worefa’ is ‘worefa’, they’ll understand it (P1, Non-patient, Male).
“Most of the things we do, we do them by ‘worefa’ even we wait in line to be blessed by
the priest’s cross. . .even you put firewood one after the other, not all at once (P4, Non-
patient, Male).
“When we take out the herd for grazing, we cast lots to decide who will tend to the cattle
first, second and so on” (P6, Non-patient, Male).
Participants suggested several ways to explain delayed treatment
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“Explain you are testing the effectiveness of the treatment, if after 12 months’ of observation
the treatment needs modification, we will modify it and the delayed group will get the
improved treatment. . .they will understand, most have lived with the disease for a long time
so waiting for another year will not be intolerable” (WoredaHealth Office expert 2).
“Assure them that they will get treated in a year and that probably they will get a better,
improved treatment, next year” (Researcher).
“These people have lived with podoconiosis for long and do not mind waiting for
another year. It is also important to inform them that although this is a small scale interven-
tion, the findings will be expanded to a large number of patients in other parts of the coun-
try” (Podoconiosis expert 2).
“You should have coffee ceremonies with patients to discuss and inform them the num-
ber of patients assigned in this group who are also waiting. Also explain that the result will
be of benefit not only for them, but for a lot of other patients in other places” (Woreda
Health Office expert 1).
Participants in the FGDs said:
“My sister is a podoconiosis patient and this is how I’ll explain it to her. . .it’s based on
chance, if her chance allows, she’ll get treated now otherwise she’ll wait for some time and
get treated” (P6, Non-patient, Male).
“Everyone will participate and no one will feel unhappy to wait. . .it’s like walking on a
narrow road where people travel in a row; one in front and another following, in the end
both will reach their destinations. . .the second group will get treated later and won’t mind
waiting”(P6, Non- patient, Male).
“Yes, we’ll wait, it is based on chance and lottery is not biased, does not favour anyone”
(P2, Patient, Female).
“Tell them in a way everyone can understand. . .for example, when the government
builds roads, they can’t build all the roads at the same time, it takes time. . .similarly, in this
research, those who get the chance will get treated first and others have to wait” (P3, Patient,
Male).
Several views were put forward regarding encouraging continued participation of the
delayed treatment group. These ranged from explaining the waiting list scenario at the IOCC
treatment and prevention project, mentioning the average waiting time, to regular meetings
with the control group, to discussing over coffee to explain the wider benefits. Several respon-
dents felt it was important to guarantee treatment for the control group after a year. However,
others seemed to suggest since all are ill and desperate, none would complain, or drop out.
“You need to be able to provide an incentive for the group that has to wait for a year. I don’t
think they will wait for a year without getting treated” (Researcher 1).
“More focus should be given to those in the delayed treatment group, as they may be
expected to complain. First, explain that a year is a short period to wait; some have waited
for 7 to 10 years to get treatment. Then explain that random selection will be used to assign
people into one of the groups, they’ll understand and be contented no one was favoured”
(Podoconiosis expert 1).
In sum, although there seemed to be a range of approaches, most participants appeared con-
fident that participants would stay in the study given these explanations.
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Discussion
This Rapid Ethical Assessment (REA) provided useful insights into many aspects of preparing
for and conducting a randomised controlled trial of podoconiosis treatment in northern Ethio-
pia. The term REA originated from Rapid Ethnographic Assessment techniques and is a pre-
liminary investigation of potential ethical issues in a setting prior to launching a study.
However, it is to be noted here that the word ‘rapid’ in Rapid Ethical Assessment, should not
be interpreted as hastening the ethical review process. In addition, REA is not a sine qua non
for all scientific research. As ethical issues in research are a function of the subject of inquiry,
design of the study, population being studied, the setting in which the study takes place and
availability of resource, these and other factors determine the need for the conduct of REA.
Accordingly, researchers in the field suggested this determination be reviewed in the light of
specific type of research proposed and provided a possible list of working criteria[15]. For
example, studies in research-naïve communities, dealing with a sensitive issues and vulnerable
population, clinical trials including studies involving collection of biologic specimen often
require REA[24].
The 6 weeks’ fieldwork activities for this REA cost around 31, 000 ETB (US $1,550). Both
teammembers had qualitative research skills and the anthropologist had previous REA experi-
ence. A recent assessment on feasibility of REA in three community based studies in Ethiopia esti-
mated an average of 42,815.5 ETB (US $2,140) and duration 4–6 weeks to conduct an REA[15].
Specific strategies adopted by the trial team included holding sensitisation meetings called
by woreda or kebele leaders (though not the police); asking Health Extension Workers to
accompany the research team to patients’ houses; employing a local health education expert to
provide information about the trial; using analogies from agriculture and local social organisa-
tions to explain randomisation; allowing time for individuals to discuss participation with their
families before committing to the trial; offering small packets of coffee to participants in the
‘delayed’ intervention arm as an incentive to continue in the trial; and using key community
members to quell rumours that arose in the course of the trial. We discuss these strategies in
the context of participants’ responses below.
Respondents suggested that information about the study should be provided through initial
sensitisation meetings called by local administrative leaders or the police. Health Extension
Workers who are known to and trusted by the community could then be asked to guide trial
team members to patients’ homes. A similar approach was used in southern Ethiopia, where
sensitisation meetings preceded introductions to specific patients, although in that context,
members of the local Patient Association accompanied the research team to patients’ homes
rather than Health Extension Workers [13]. The approach adopted for this trial was first to
give information to woreda representatives, kebele chairs, community and religious leaders,
who all disseminated the information further. Health Extension Workers were then briefed
and asked to list patients with podoconiosis and lead trial team members to their houses.
Using the police to approach communities for sensitisation about a study has not been
reported in other contexts, and we were surprised this group was mentioned. However, a recent
case study among police officers, academics, civil society and the judicial sectors in Amhara
regional state, suggests that community policing has improved community-police relations in the
region. The manner in which community members view Community Police Officers has gradu-
ally changed so they are now considered to be respected community representatives who play a
range of social service functions that fall outside traditional policing purviews [25]. However, this
approach was not employed, given that its potential for undue influence and the impact it might
have on the voluntariness of the informed consent process was unclear. Whether these roles
might be extended to community sensitisation would be an interesting focus for future research.
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Participants preferred information about the trial to be delivered by a person who under-
stands the local culture. While the entire trial team spoke Amharic (the language used in this
setting), and several had grown up in Amhara region, we found that local variations in dialect
meant that detailed information was best conveyed by a health educator from East Gojjam
zone itself. This individual joined the trial team for enrolment days, explained the trial,
answered questions and probed comprehension before consent was requested [26]. In previous
studies which have employed REA, consent processes have significantly improved in terms of
both comprehension and decision making as a result of the knowledge and understanding
gained [15] as well as facilitating ethically and scientifically sound practice around recruitment
and retention of trial participants[13].
In the trial, information was initially given to patients as a group where they were encouraged
to ask questions. Their understanding of this information was verified when consent to partici-
pate was requested individually. This mirrored procedures followed after REA inWolaita,
southern Ethiopia, where in the subsequent genetic study, information was provided through
group discussions and decisions were reached after consultation with family members, neigh-
bours and friends[9]. The information given in the present trial included the objectives of the
study, study procedures, risks and benefits of participation, participants’ rights, how informa-
tion was to be stored, confidentiality of personal record, and who the investigators were. This
was despite many experts in this REA suggesting playing down the risks of participation. They
justified concealing risks on the assumption that potential participants would find complete dis-
closure ‘boring’ or incomprehensible. A similar study in southern Ethiopia reported that the
information participants most wanted to hear was the expected benefit of the research[9].
Underestimation of the potential risks attached to research, particularly in the context of a
clinical trial, would weaken the informed consent process [2–4, 27]. Informed consent presup-
poses that subjects understand the potential risks and benefits of their participation, and that it
is research, not therapy, in which they will participate [28]. Misunderstood study risks have
critical ethical consequences. For example, without fully understanding a study’s risks, partici-
pants cannot make an informed decision as to the level of risks they are willing to accept by
participating. The Declaration of Helsinki specifies that adequate communication of study
risks is imperative for ethical research[2]. Accordingly, in the four-page information sheet the
following relevant information was explained (Box 1). In addition, all study staff including
investigators and fieldworkers were required to take an online International Conference on
Harmonisation, Good Clinical Practice (ICH-GCP) course and certification (Globalhealth-
trials.org).
Some participants identified differential decision-making power between men and women.
Participants in women’s focus groups argued that the decision should be consultative within
the family, for both men and women. In addition, they said that where women were heads of
households through divorce or widowhood, they could decide without consulting others.
While most participants in a REA conducted in Cameroon advocated male responsibility for
giving consent[29], it appears that in the context of northern Ethiopia, women can be
approached for and provide consent in consultation with their families or by themselves.
Unlike the REA study in Cameroon[29], but in line with the one in southern Ethiopia[9], the
permission of local traditional authorities and community leaders was not required before indi-
vidual consent to participate in a study was given. The role suggested here for local community
and religious leaders, was to facilitate entry into the community and rectify false information
about the study when it arises. Proxy decision-making is not advocated in this community, but
has been by other REA respondents, for example in north-west Cameroon (21). National and
international guidelines for ethical conduct in research recognize that some standards, such as
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that requiring individual informed consent be given voluntarily by competent participants,
must be met whatever the cultural context within which research is conducted [3–4, 27, 30].
Although participants in focus groups could not identify factors that might hinder partici-
pation in the trial, experts raised some concerns. For example, the longer the gap between wor-
eda/kebele level sensitisation and approaching individual patients, the more likely that
misleading information would reach the communities. In order to prevent misconceptions,
garnering the support of community, religious and political leaders to quell rumours was
thought to be important. The trial team used this approach during enrolment in one kebele; to
counter misconceptions being spread by individuals who were opposed to the trial. For exam-
ple, during group information provision at enrolment, prospective participants questioned
whether the treatment works at all based on information from a fellow patient (who refused
participation) claiming health professional advice that this is an incurable disease and that the
only treatment to improve the condition is surgical removal of the affected leg. In another
instance, subjects speculated that the true intent of the trial, as rumour had it, was religious
conversion.
Although some participants considered randomisation to be the most difficult concept for
prospective participants to understand, several strategies were suggested. Agricultural analogies
were thought to be useful ways of explaining the two intervention groups. The concept of the
lottery method (‘Ita’ in the Amharic language) is well known in these communities and is used
Box 1: Sections of the trial Information Sheet and Consent Form
Heading
Study title: Randomized controlled trial of podoconiosis treatment in northern Ethiopia
Lay title: A study of the treatment of podoconiosis in northern Ethiopia
Names and institutional affiliations of investigators
Main body
Introduction; Your illness; What is IOCC; What is the study about; Study procedures;
How are participants selected; How are participants allocated to study arms; What will
participating involve; Are there risks or disadvantages to me of participating in the study;
Are there any benefits to me of participating in the study; What happens if I refuse to
participate; Where can I get alternative treatment; Who will have access to my informa-
tion; What happens to the blood sample; What if I have any questions; Who allowed
this research to take place; Who is organizing and funding the research; Your under-
standing of the information we gave you about the study and Consent Form.
*Footer
Names, institutions and contact telephone numbers for further enquiries (if needed):
About the GoLBet trial: the trial co-ordinator and data manager; Head ofWoreda
Health Office; Amhara Regional Health Bureau
About participants’ rights and trial related safety: The trial’s Local Safety Monitor;
Institutional Review Board, College of Health Sciences, Addis Ababa University.
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in social, financial and religious activities. These analogies were all used at times in explaining
the trial to potential participants.
To encourage continued participation of the control group, respondents suggested that the
IOCC waiting list was used as an example of delayed treatment. Other suggestions included
guaranteeing treatment for the control group through meetings at different stages of the trial,
and providing small incentives to the control group in the form of packets of coffee to encour-
age continued participation in the trial. All these strategies were used in the actual trial. For
example, the IOCC waiting list scenario and waiting time was explained in the information
sheet. In addition, at regular follow-up study visits, participants in the delayed treatment group
were informed of the time remaining before they received treatment and given small packets of
coffee. It was also explained that participation would help provide evidence on the effectiveness
of the treatment for policy formulation at national and international levels, and thus benefit a
large number of people with podoconiosis in other places.
There are several limitations of this study. Despite efforts to identify the most productive
sample to answer the study questions, by varying location, participants of the focus groups
were selected by Health Extension Workers, which may have introduced selection bias. This in
turn may have resulted in social desirability bias. For example, HEWs might have selected peo-
ple they know or who they thought or trusted to provide the “right” responses rather than a
“troublemaker”. Focus group participants seemed to suggest there was no reason that patients
might decline to participate. This might be because they themselves thought the project was
treatment instead of research.
Box 2: Section of the Information Sheet explaining randomisation
and delayed treatment
How are patients allocated to study arms?
Assume the woreda agriculture office wanted to check the effectiveness of a new fertilizer
in terms of yield and making the soil fertile before giving the fertilizer to all farmers in
the woreda. The office selected plots from farmers who volunteer to take part, spread the
fertilizer only on some selected plots and not on the others. Then, a year later they com-
pared the yield of plots with the new fertilizer with those without it. Based on this com-
parison, the agriculture office would either provide the fertilizer to all farmers or would
not. Similarly, the GoLBet will test the effectiveness of the treatment of podoconiosis on
patients who are willing to take part in the study by assigning them into one of two study
groups: ‘immediate’ treatment’, or ‘delayed treatment’. Those in the ‘immediate’ treat-
ment group will receive treatment immediately for a year while those in the ‘delayed'
treatment group will be offered the same treatment a year later. This will help us find out
if there is any difference between the two groups by closely watching the progress of
everyone in this study. A total of 680 patients (340 in each arm) will participate in the
study with duration of one year participation in the study for any given patient. The deci-
sion on which any person gets to be allocated to which group will be decided by a system
based on chance, not by anyone in the research team. Study numbers we give for individ-
ual patients who meet the selection criteria will be fed into a computer which will make
allocation based a lottery method. This will be done by experts at Kilifi Clinical Trials
Facility in Kenya.
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In order to reduce the effect of the ‘therapeutic misconception’ in the actual trial, the differ-
ence between research and treatment was clearly explained in the information sheet. For exam-
ple, the section of the information sheet about the study was explained as follows: “. . .we’re
trying to learn more about the effectiveness of the treatment of podoconiosis. Experience from
NGOs so far has shown the current treatment for podoconiosis to work and to be safe. How-
ever, more research is required to test the effectiveness the treatment. Unlike projects which
are mainly focused on provision of prevention and treatment services, the GoLBet [the trial]
study is mainly focused on finding out evidence about the effectiveness of the current treatment
and make it widely available in the future for everybody’s benefit”. In addition, randomisation
and delayed treatment were explained (Box 2).
Finally, during the provision of the information and before individual consent was given,
subjects were encouraged to ask questions and describe in their own words important aspects
of the study including the aims and procedures of the study, awareness of risks and benefits,
privacy, voluntary participation, awareness of the possibility of withdrawing at any time and
understanding how to get further information.
Interviews were conducted in Amharic, and analysis was done in English. Preferably, quali-
tative data analysis should be conducted in the language of interview to minimise loss of mean-
ing during translation.
In closing, this REA provided useful information for preparing for and conducting a rando-
mised controlled trial of podoconiosis treatment in northern Ethiopia. This study highlights
the utility of rapid ethical assessment prior to clinical trials involving complex procedures and
concepts.
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